| Literature DB >> 28768725 |
Lisa Borkner1, Katarzyna M Sitnik1, Iryna Dekhtiarenko1, Ann-Kathrin Pulm1, Ronny Tao2, Ingo Drexler2, Luka Cicin-Sain3,4,5.
Abstract
Experimental CMV-based vaccine vectors expressing a single MHC class I-restricted high-avidity epitope provided strong, T cell-dependent protection against viruses or tumors. In this study we tested the low-avidity epitope KCSRNRQYL, and show that a mouse CMV (MCMV) vector provides complete immune control of recombinant vaccinia virus expressing the same epitope if KCSRNRQYL is expressed within the immediate-early MCMV gene ie2 The same epitope expressed within the early M45 gene provided no protection, although MCMV vectors expressing the high-avidity epitope SSIEFARL induced protective immunity irrespective of gene expression context. Immune protection was matched by Ag-induced, long-term expansion of effector memory CD8 T cells, regardless of epitope avidity. We explained this pattern by observing regularities in Ag competition, where responses to high-avidity epitopes outcompeted weaker ones expressed later in the replicative cycle of the virus. Conversely, robust and early expression of a low-avidity epitope compensated its weak intrinsic antigenicity, resulting in strong and sustained immunity and immune protection.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28768725 DOI: 10.4049/jimmunol.1602115
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422